%PDF-1.4
%
38 0 obj
<>
endobj
35 0 obj
<>
endobj
112 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-09T14:59:22Z
2024-03-29T07:55:37-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T07:55:37-07:00
application/pdf
Heather
2001-827.august
uuid:426bd91c-1dd2-11b2-0a00-dc0827fd5800
uuid:426bd91f-1dd2-11b2-0a00-6a0000000000
endstream
endobj
24 0 obj
<>
endobj
25 0 obj
<>
endobj
39 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
132 0 obj
[136 0 R]
endobj
133 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 0.1778 Tw 10 0 0 10 66 713.1616 Tm
[(Another important dif)17.7 (ference of our BD patients from)]TJ
0 Tc 0.3002 Tw -1.2 -1.2 Td
(other ethnic groups is the low frequency of a positive)Tj
0.05299 Tw 0 -1.2 TD
[(pather)17.8 (gy test. )17.8 (The positivity of the pather)17.8 (gy reaction varies)]TJ
-0.00011 Tc 0.00211 Tw T*
[(widely in dif)17.7 (ferent populations \(8\22677%\))]TJ
0 Tc 0 Tw 6.5 0 0 6.5 214.96 680.4615 Tm
(3)Tj
-0.0157 Tw 10 0 0 10 218.2099 677.1616 Tm
[(. While )-17.8 (pather)17.8 (gy )-17.7 (is)]TJ
0.1815 Tw -16.421 -1.2 Td
(considered to be highly sensitive and specific in patients)Tj
0.0153 Tw T*
[(with BD from Japan and )17.8 (T)34.9 (urkey)64.9 (, it is frequently negative in)]TJ
0.28239 Tw T*
[(patients from the )17.8 (W)79.8 (estern countries)]TJ
0 Tw 6.5 0 0 6.5 207.0331 644.4615 Tm
(3,6,25,26)Tj
0.22749 Tw 10 0 0 10 231.4079 641.1616 Tm
[(. Although )-54.9 (the)]TJ
0.0677 Tw -17.7408 -1.2 Td
[(positivity of the pather)17.8 (gy reaction depends on a number of)]TJ
-0.00011 Tc 0.1447 Tw T*
[(factors such as disease activity)64.8 (, sex, HLA-B51 status, the)]TJ
0 Tc 0.2009 Tw T*
(size and type of the needle used, number of pricks, and)Tj
0.283 Tw T*
(whether an antiseptic is used to clean the skin)Tj
-0.00011 Tc 0 Tw 6.5 0 0 6.5 259.3495 596.4615 Tm
(27-29)Tj
0.283 Tw 10 0 0 10 274.5123 593.1616 Tm
(, we)Tj
0 Tc 0.3004 Tw -22.0512 -1.2 Td
(believe that the low prevalence of this reaction in our)Tj
0.0013 Tw T*
(Chinese patients is genuine because a standard procedure of)Tj
0.2702 Tw T*
(the test was being followed by our investigators)Tj
0 Tw 6.5 0 0 6.5 264.2504 560.4615 Tm
(25)Tj
-0.00011 Tc 0.27029 Tw 10 0 0 10 270.7503 557.1616 Tm
(. Our)Tj
0 Tc 0.0519 Tw -21.675 -1.2 Td
[(results support the observation that the pather)17.8 (gy reaction is)]TJ
-0.00011 Tc 0.1842 Tw T*
(not sensitive for the diagnosis of BD in areas where the)Tj
0 Tc 0.1586 Tw T*
[(prevalence of the disease is low)65 (. )17.7 (Whether the low preva-)]TJ
0.1264 Tw T*
[(lence of the pather)17.8 (gy reaction in our series is related to a)]TJ
0.0249 Tw T*
[(dif)17.8 (ferent HLA)-220.1 (association of the disease remains elusive.)]TJ
0.19791 Tw 1.2 -1.2 Td
(BD is rare among southern Chinese residing in Hong)Tj
0.02 Tc 0.3687 Tw -1.2 -1.2 Td
(Kong. Compared with other ethnic groups, southern)Tj
0 Tc 0.0229 Tw T*
(Chinese patients tend to run a more benign course with less)Tj
-0.0282 Tw T*
[(serious ocular complications and systemic involvement. )17.8 (The)]TJ
0.2061 Tw T*
[(pather)17.8 (gy reaction is uncommon and insensitive for diag-)]TJ
0.13361 Tw T*
[(nosis of the disease in our locality)65 (. )17.8 (Whether the observed)]TJ
-0.02409 Tw T*
[(dif)17.8 (ference in disease manifestations of our patients is related)]TJ
0.0193 Tw T*
[(to a dif)17.8 (ferent HLA)-214.4 (association or linkage to the MIC alleles)]TJ
-0.00011 Tc 0.02499 Tw T*
(warrants further evaluation.)Tj
/TT1 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/TT0 1 Tf
0 Tc 0.0249 Tw 8 0 0 8 61 355.1616 Tm
[(1.)-875 (Beh\347et H. Uber Rezidivierende )54.8 (Aphtose durch ein virus verusachte)]TJ
1.675 -1.25 Td
[(Geschwure am Mund, am )54.8 (Auge und an den Genitalien. Dermatol)]TJ
0 -1.25 TD
[(W)79.8 (ochenschr 1937;105:1)36.9 (152-7.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(2.)-875.1 (James DG. Silk Route disease. Postgrad Med J 1986;62:151-3.)]TJ
T*
[(3.)-875.1 (Kaklamani )17.7 (VG, )17.7 (V)111 (aiopoulos G, Kaklamanis PG. Beh\347et\222)54.8 (s disease.)]TJ
0 Tc 1.675 -1.25 Td
[(Semin )54.9 (Arthritis Rheum 1998;27:197-217.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875.1 (Kastner DL. Intermittent and periodic arthritic syndromes. In:)]TJ
0 Tc 1.675 -1.25 Td
[(Koopman EJ, editor)54.9 (. )54.9 (Arthritis and allied conditions: a textbook of)]TJ
T*
[(rheumatology)64.9 (. 13th ed. )17.8 (V)129.2 (ol 1. Baltimore: )17.8 (W)39.8 (illiams & )17.8 (W)39.8 (ilkins;)]TJ
0 Tw T*
(1997:1279-306.)Tj
0.0249 Tw -1.675 -1.25 Td
[(5.)-875 (Sakane )17.7 (T)74 (, )17.7 (T)69.8 (akeno M, Suzuki N, Inaba G. Beh\347et\222)54.9 (s disease. New)]TJ
1.675 -1.25 Td
(Engl J Med 1999;341:1284-91.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(6.)-875.1 (Davies PG, Fordham JN, Kirwan JR, Barnes CG, Dinning )17.7 (WJ. )17.7 (The)]TJ
0 Tc 1.675 -1.25 Td
[(pather)17.8 (gy test and Beh\347et\222)54.9 (s syndrome in Britain. )54.8 (Ann Rheum Dis)]TJ
0 Tw T*
(1984;43:70-3.)Tj
0.02499 Tw -1.675 -1.25 Td
[(7.)-875 (Krause I, Leibovici L, Guedj D, Molad )36.8 (Y)129.1 (, Uziel )36.9 (Y)129.1 (, )17.8 (W)79.8 (einber)17.8 (ger )54.9 (A.)]TJ
-0.00011 Tc 1.675 -1.25 Td
[(Disease patterns of patients with Beh\347et\222)54.8 (s disease demonstrated by)]TJ
0 Tc T*
(factor analysis. Clin Exp Rheumatol 1999;17:347-50.)Tj
-1.675 -1.25 Td
[(8.)-875 (O\222Neill )17.7 (T)74 (, Rigby )54.8 (AS, McHugh S, Silman )54.8 (AJ, Barnes C. Regional)]TJ
1.675 -1.25 Td
[(dif)17.8 (ferences in clinical manifestations of Beh\347et\222)54.9 (s disease. In:)]TJ
-0.00011 Tc T*
[(W)79.7 (echsler B, Godeau P)110.7 (,)-0.1 ( editors. Beh\347et\222)54.8 (s disease. Proceedings of the)]TJ
0 Tc T*
[(6th International Conference on Beh\347et\222)54.9 (s disease. )54.8 (Amsterdam:)]TJ
T*
(Excerpta Medica; 1993;159-63.)Tj
-1.675 -1.25 Td
[(9.)-875 (Kone-Paut I, )36.8 (Y)111.1 (urdakul S, Bahabri SA, et al. Clinical features of)]TJ
1.675 -1.25 Td
[(Beh\347et\222)54.9 (s disease in children: an international collaborative study of)]TJ
T*
(86 cases. J Pediatr 1998;132:721-5.)Tj
-2.175 -1.25 Td
[(10.)-875 (Mineshita S, )17.7 (T)34.9 (ian D, )17.7 (W)79.8 (ang LM, et al. Histocompatibility antigens)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(associated with Beh\347et\222)54.8 (s disease in northern Han Chinese. Intern)]TJ
0 Tc T*
(Med 1992;31:1073-5.)Tj
-0.00011 Tc 30.8619 79.921 Td
[(1)36.8 (1)-0.1 (.)-875.1 (International Study Group for Beh\347et\222)54.8 (s Disease: Criteria for)]TJ
0 Tc 2.1381 -1.25 Td
[(diagnosis of Beh\347et\222)54.9 (s disease. Lancet 1990;335:1078-80.)]TJ
-2.175 -1.25 Td
[(12.)-875 (2001 Population Census. Census and Statistics Department, Hong)]TJ
2.175 -1.25 Td
[(Kong Special )54.9 (Administrative Region, China.)]TJ
-2.175 -1.25 Td
[(13.)-875 (Zouboulis CC, Kotter I, Djawari D, et al. Epidemiological features)]TJ
2.175 -1.25 Td
[(of )54.9 (Adamantiades-Beh\347et\222)54.9 (s disease in Germany and in Europe.)]TJ
T*
[(Y)100.1 (onsei Med J 1997;38:41)36.9 (1-22.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875.1 (Dilsen N, Konice M, )54.8 (Aral O, Ocal L, Inanc M, Gill )54.8 (A. Risk factors)]TJ
2.175 -1.25 Td
[(for vital or)17.7 (gan involvement in Beh\347et\222)54.8 (s disease. In: )17.7 (W)79.7 (echsler B,)]TJ
T*
[(Godeau P)110.7 (,)-0.1 ( editors. Beh\347et\222)54.8 (s disease, Proceedings of the 6th)]TJ
0 Tc T*
[(International Conference on Beh\347et\222)54.9 (s disease. )54.8 (Amsterdam: Excerpta)]TJ
T*
(Medica; 1993:165-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875.1 (Mousa )54.8 (AR, Marafie )54.8 (AA, Rifai KM, Dajani )54.8 (AI, Mukhtar MM.)]TJ
2.175 -1.25 Td
[(Beh\347et\222)54.8 (s disease in Kuwait, )54.8 (Arabia. )54.8 (A)-219.9 (report of 29 cases and a)]TJ
0 Tc T*
[(review)64.9 (. Scand J Rheumatol 1986;15:310-32.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875.1 (Gonzalez-Gay MA, Garcia-Porrua C, Branas F)79.7 (,)-0.1 ( Lopez-Lazaro L,)]TJ
0 Tc 2.175 -1.25 Td
[(Olivieri I. Epidemiologic and clinical aspects of Beh\347et\222)54.9 (s disease in)]TJ
T*
(a defined area of Northwestern Spain, 1988-1997. J Rheumatol)Tj
0 Tw T*
(2000;27:703-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (Zouboulis CC, Buttner P)110.7 (, Djawari D, et al. HLA-class I antigens in)]TJ
0 Tc 2.175 -1.25 Td
[(German patients with )54.8 (Adamantiades-Beh\347et\222)54.9 (s disease and)]TJ
T*
[(correlation with clinical manifestations. In: )17.7 (W)79.8 (echsler B, Godeau P)110.8 (,)]TJ
T*
[(editors. Beh\347et\222)54.9 (s disease. Proceedings of the 6th International)]TJ
T*
[(Conference on Beh\347et\222)54.9 (s disease. )54.8 (Amsterdam: Excerpta Medica;)]TJ
0 Tw T*
(1993:175-80.)Tj
0.0249 Tw -2.175 -1.25 Td
[(18.)-875 (Koumantaki )36.8 (Y)129.2 (, Stavropoulos C, Spyropoulou M, et al. HLA-)]TJ
2.175 -1.25 Td
[(B*5101 in Greek patients with Beh\347et\222)54.9 (s disease. Hum Immunol)]TJ
0 Tw T*
(1998;59:250-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(19.)-875.1 (Kilmartin DJ, Finch )54.8 (A, )54.8 (Acheson R)54.8 (W)91.7 (. Primary association of HLA-)]TJ
2.175 -1.25 Td
[(B51 with Beh\347et\222)54.8 (s disease in Ireland. Br J Ophthalmol)]TJ
0 Tc 0 Tw T*
(1997;81:649-53.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875.1 (Demiroglu II, Barista I, Dundar S. Risk factor assessment and)]TJ
0 Tc 2.175 -1.25 Td
[(prognosis of eye involvement in Beh\347et\222)54.9 (s disease in )17.7 (T)34.9 (urkey)64.9 (.)]TJ
T*
(Ophthalmology 1997;104:701-5.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(21.)-875.1 (Y)100 (azici H, Chamberlain MA, Schreuder I, D\222Amaro J, Muftuoglu)]TJ
0 Tc 2.175 -1.25 Td
[(M. HLA)-220.1 (antigens in Beh\347et\222)54.9 (s disease: a reappraisal by a)]TJ
T*
[(comparative study of )17.7 (T)34.9 (urkish and British patients. )54.8 (Ann Rheum Dis)]TJ
0 Tw T*
(1980;39:344-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875.1 (Gul )54.8 (A, Hajeer )54.8 (AH, )17.7 (W)79.7 (orthington J, Barrett JH, Ollier )17.7 (WE, Silman)]TJ
0 Tc 2.175 -1.25 Td
[(AJ. Evidence for linkage of the HLA-B locus in Beh\347et\222)54.9 (s disease,)]TJ
T*
[(obtained using the transmission disequilibrium test. )54.9 (Arthritis)]TJ
T*
(Rheum 2001;44:239-40.)Tj
-2.175 -1.25 Td
[(23.)-875 (Salvarani C, Boiardi L, Mantovani )17.7 (V)129.1 (, et al. )54.8 (Association of MICA)]TJ
2.175 -1.25 Td
[(alleles and HLA-B51 in Italian patients with Beh\347et\222)54.9 (s disease. )]TJ
T*
(J Rheumatol 2001;28:1867-70.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(24.)-875.1 (Mizuki N, Ota M, Katsuyama )36.8 (Y)129.1 (,)-0.1 ( et al. )54.8 (Association analysis between)]TJ
0 Tc 2.175 -1.25 Td
[(the MIC-A)-220.1 (and HLA-B alleles in Japanese patients with Beh\347et\222)54.9 (s)]TJ
T*
[(disease. )54.9 (Arthritis Rheum 1999;42:1961-6.)]TJ
-2.175 -1.25 Td
[(25.)-875 (Y)100.1 (azici H, Chamberlain MA, )17.7 (T)34.9 (uzun )36.8 (Y)129.1 (, )36.8 (Y)111.1 (urdakul S, Muftuoglu )54.8 (A. )54.9 (A)]TJ
2.175 -1.25 Td
[(comparative study of the pather)17.8 (gy reaction among )17.7 (T)34.9 (urkish and)]TJ
T*
[(British patients with Beh\347et\222)54.9 (s disease. )54.8 (Ann Rheum Dis 1984;)]TJ
0 Tw T*
(43:74-5.)Tj
0.0249 Tw -2.175 -1.25 Td
[(26.)-875 (O\222Duf)17.8 (fy JD. Beh\347et\222)54.9 (s disease. Curr Opin Rheumatol 1994;6:39-43.)]TJ
-0.00011 Tc T*
[(27.)-875.1 (Dilsen N, Konice M, )54.8 (Aral O, Ocal L, Inanc M, Gul )54.8 (A. Comparative)]TJ
0 Tc 2.175 -1.25 Td
[(study of the skin pather)17.8 (gy test with blunt and sharp needles in)]TJ
T*
[(Beh\347et\222)54.9 (s disease: confirmed specificity but decreased sensitivity)]TJ
T*
[(with sharp needles. )54.8 (Ann Rheum Dis 1993;52:823-5.)]TJ
-2.175 -1.25 Td
[(28.)-875 (Fresko I, )36.8 (Y)100.1 (azici H, Bayramicli M, )36.8 (Y)111.1 (u)0.1 (rdakul S, Mat C. Ef)17.8 (fect of)]TJ
2.175 -1.25 Td
[(sur)17.8 (gical cleaning of the skin on the pather)17.8 (gy phenomenon in)]TJ
T*
[(Beh\347et\222)54.9 (s syndrome. )54.8 (Ann Rheum Dis 1993;52:619-20.)]TJ
-0.0119 Tw -2.175 -1.25 Td
[(29.)-875 (Y)100.1 (azici )-36.9 (H, )-19.1 (T)34.9 (uzun Y)129.1 (,)0.1 ( )-36.8 (Pazarli )-36.8 (H, Y)100.1 (alcin )-36.9 (B, Y)111.1 (urdakul )-36.8 (S, )-36.9 (Muftuoglu )18 (A.)]TJ
0.02499 Tw 2.175 -1.25 Td
[(The combined use of HLA-B5 and the pather)17.8 (gy test as diagnostic)]TJ
-0.00011 Tc T*
[(markers of Beh\347et\222)54.8 (s disease in )17.7 (T)34.8 (urkey)64.8 (. J Rheumatol 1980;7:206-10.)]TJ
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT2 1 Tf
0 Tc 8 0 0 8 54.5 35.9844 Tm
(Mok, et al: BD in Chinese patients)Tj
0 Tw 60.9375 -0.0313 Td
(1693)Tj
ET
0 0 0 0 scn
/GS0 gs
100.56 58.37 407.5 -10.83 re
f*
0.5 w
100.56 58.37 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
77 0 obj
<>
endobj
117 0 obj
<>
endobj
46 0 obj
<>
endobj
14 0 obj
<>
endobj
41 0 obj
<>
endobj
43 0 obj
<>
endobj
71 0 obj
<>stream
HV
pMg~soBD'GRMrA/E_~)RA&&ShKWڱR6֎b1~v5H[Usnjgv|y}=~@AA2{M>ұ%9A VTw,k@X^5rsEq˚?qeW sG[qX+m+*v|M@
3ď!MGTVɷgWe^fUπ`V_V9b,R:G\#n`/%؆DžX&@3K0E"< XA;vT8RzP^OE.m?fe,.lN XkyG%an:)jTJzW)DAϝvpUxr8(|4+09UHw-Va91MV+VҮקE6~qj$iu6[!;JhHF7Q;3~Yc"B䈡"_,C*ne[ҺYw